Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The most proven dividend growth stocks can be equivalent to a money tree for shareholders. Even as demand for its COVID-19 diagnostic tests continued to fall, Abbott Laboratories outpaced the analyst consensus in the third quarter. The company's interest coverage ratio through the first three quarters of 2023 was nearly 30.

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

In the closing of the recent trading day, Abbott (ABT) stood at $109.79, denoting a +0.51% change from the preceding trading day.

Abbott (ABT) Laps the Stock Market: Here's Why

Humana

McKesson

Finding investment opportunities in tune with today's demographic trends can be challenging, but aging population stocks may be the solution. This market is booming in a world with an aging population, creating a special opportunity for investors to profit.

Silver Economy Successes: 3 Stocks Benefitting From an Aging Population

Apple

Johnson & Johnson

Coca-Cola

Vertex Pharmaceuticals

Your year-end bonus looks great now. But it may look even better in a few years if you invest it in some top-quality stocks.

5 Top Stocks to Buy With Your End-of-the-Year Bonus

PetIQ

Investors looking for stocks in the Medical - Products sector might want to consider either PetIQ (PETQ) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

PETQ or ABT: Which Is the Better Value Stock Right Now?

AbbVie

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Cardinal Health

Caterpillar

Chubb

Church & Dwight

C.H. Robinson Worldwide

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Dover

Ecolab

The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats by quality score and provide undervalued stocks for further research and investment.

29 Undervalued Dividend Aristocrats: December 2023

AbbVie is a top drugmaker that is putting its free cash flow to use lately with a couple of acquisitions. Abbott Labs has a broader, more diverse business that recently generated double-digit growth.

Better Growth Stock: AbbVie vs. Abbott Laboratories

Abbott (ABT) reachead $108.42 at the closing of the latest trading day, reflecting a +0.33% change compared to its last close.

Here's Why Abbott (ABT) Gained But Lagged the Market Today

Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.

Abbott (ABT) Gains From Global Expansion Amid Macro Woes

ABBOTT PARK, Ill., Dec. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 42nd annual J.P.

Abbott to Present at J.P. Morgan Healthcare Conference

General Mills

Hormel Foods

Procter & Gamble

Starbucks

AT&T

Verizon

With the markets at or near all time highs, after a wild up and down 2023, I could find comfort in one thing, my dividends. As we all know, the market may move up and down irrationally and seemingly on a whim, while our dividends remain much more stable, reliable and predictable. Another four figures coming in a particular month is nothing to sneeze at. I'll definitely take it, as passive income always seems a little sweeter than active income.

Dividend Income Update November 2023

Dividend increased by 7.8% 400th consecutive quarterly dividend to be paid by Abbott since 1924 Company continues to deliver strong shareholder returns and top-tier growth ABBOTT PARK, Ill., Dec. 15, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 55 cents per share, an increase of 7.8%.

Abbott Increases Quarterly Dividend for 52nd Consecutive Year

Moderna

Pfizer

Investors loved these stocks earlier in the pandemic -- but they've since fallen out of favor. They actually make terrific long-term buys, though, and today you can pick them up for a steal.

3 No-Brainer Healthcare Stocks to Buy Right Now

Abbott (ABT) concluded the recent trading session at $106.68, signifying a +0.43% move from its prior day's close.

Abbott (ABT) Advances But Underperforms Market: Key Facts

Intuitive Surgical

Abbott Labs has a strong brand name and solid growth avenues despite coronavirus-related issues. Intuitive Surgical's dominance in robotic-assisted surgery is an excellent sign for the company's future.

2 Healthcare Stocks to Buy Hand Over Fist in December

Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?

PETQ vs. ABT: Which Stock Is the Better Value Option?

In 2023, AI and the Magnificent 7 took the lead, leaving non-tech blue chip companies trailing behind in the rearview mirror. Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted. Yet, Abbott operates a recession-proof business model with long-term tailwinds, its core business growing at double digits.

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Abbott Laboratories is a stable investment in challenging times, with an AA- credit rating and a history of surviving economic downturns. ABT has a well-diversified healthcare portfolio, including diagnostics, medical devices, and pharmaceuticals, positioning it to address evolving healthcare challenges. Despite a temporary stock dip, ABT has shown robust financial performance with impressive growth across segments, reflecting resilience and sales expansion.

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.

Abbott (ABT) Benefits From Innovation Amid FX Headwinds

Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

PETQ vs. ABT: Which Stock Should Value Investors Buy Now?

DexCom

Ozempic could lead to patients needing to buy fewer interventions for diabetes. It could also do the same for certain cardiovascular interventions.

Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue?

After reaching an important support level, Abbott (ABT) could be a good stock pick from a technical perspective. ABT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Abbott (ABT) Just Overtook the 50-Day Moving Average

New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots More than 30,000 people worldwide have received Abbott's life-saving heart pump to overcome advanced heart failure ABBOTT PARK, Ill., Nov. 13, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant.

Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump

AstraZeneca

Anheuser-Busch InBev

Crown Hlds

Chipotle

DoorDash

That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.

News for Abbott Labs Stock (ABT)